证券代码：688136 证券简称：科兴制药 公告编号：2025-095 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 根据 2025 年 11 月 17 日询价申购情况，初步确定的本次询价转让价格为 30.05 元/股。 受让方通过询价转让受让的股份，在受让后 6 个月内不得转让。 一、本次询价转让初步定价 （一）经向机构投资者询价后，初步确定的转让价格为 30.05 元/股。 （二）参与本次询价转让报价及申购的机构投资者家数为 24 家，涵盖了基 金管理公司、合格境外机构投资者、证券公司、私募基金管理人等专业机构投资 者。参与本次询价转让报价及申购的机构投资者合计有效认购股份数量为 14,877,000 股，对应的有效认购倍数为 1.48 倍。 （三）本次询价转让拟转让股份已获全额认购，初步确定受让方为 12 家机 构投资者，拟受让股份总数为 10,062,800 股。 科兴生物制药股份有限公司 股东询价转让定价情况提示性公告 深圳科益医药控股有限公司保证向科兴生物制药股份有限公司（以下简称 "公司"）提供的信息内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其真 ...

关于发行境外上市股份（H 股）备案申请材料 获中国证监会接收的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688136 证券简称：科兴制药 公告编号：2025-096 科兴生物制药股份有限公司 公司已根据相关规定向中国证券监督管理委员会（以下简称"中国证监会"） 报送了本次发行上市的备案申请材料，并于近日获中国证监会接收。 公司本次发行上市尚需取得中国证监会、香港证券及期货事务监察委员会和 香港联交所等相关监管机构、证券交易所的备案、批准或核准，该事项仍存在不 确定性。公司将根据该事项的进展情况依法及时履行信息披露义务，敬请广大投 资者注意投资风险。 特此公告。 科兴生物制药股份有限公司董事会 2025 年 11 月 18 日 科兴生物制药股份有限公司（以下简称"公司"）已于 2025 年 11 月 6 日向香 港联合交易所有限公司（以下简称"香港联交所"）递交了发行 H 股股票并在香港 联交所主板挂牌上市（以下简称"本次发行上市"）的申请，并于同日在香港联交 所网站刊登了本次发行上市的申请材料。具体内 ...

科兴制药晚间公告，公司已于2025年11月6日向香港联交所递交了发行H股股票并在香港联交所主板挂 牌上市的申请。同时，公司已向中国证监会报送了本次发行上市的备案申请材料，并于近日获中国证监 会接收。公司本次发行上市尚需取得中国证监会、香港证券及期货事务监察委员会和香港联交所等相关 监管机构、证券交易所的备案、批准或核准。 ...

科兴制药公告，根据2025年11月17日询价申购情况，初步确定的本次询价转让价格为30.05元/股。本次 询价转让拟转让股份已获全额认购，初步确定受让方为12家机构投资者，拟受让股份总数为1006.28万 股。参与本次询价转让报价及申购的机构投资者家数为24家，涵盖了基金管理公司、合格境外机构投资 者、证券公司、私募基金管理人等专业机构投资者。参与本次询价转让报价及申购的机构投资者合计有 效认购股份数量为1487.7万股，对应的有效认购倍数为1.48倍。 ...

Market Overview - The biopharmaceutical sector experienced a decline of 1.94% on November 17, with Kexing Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Bohui Innovation: Closed at 8.00, up 2.56% with a trading volume of 824,300 shares [1] - ST Weiming: Closed at 8.31, up 2.21% with a trading volume of 60,800 shares [1] - Major decliners included: - Kexing Pharmaceutical: Closed at 34.59, down 7.88% with a trading volume of 53,300 shares [2] - Jinwei: Closed at 26.05, down 7.06% with a trading volume of 123,100 shares [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 1.211 billion yuan from institutional investors, while retail investors contributed a net inflow of 893 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Notable capital flows for specific stocks included: - Wanzhe Co.: Net outflow of 37.20 million yuan from institutional investors [3] - Olin Bio: Net inflow of 13.81 million yuan from institutional investors [3] - The data reflects varying levels of investor confidence across different companies within the sector [3]

Market Overview - Major A-share indices collectively declined, with the Shanghai Composite Index down 0.46% closing at 3972 points, and the Shenzhen Component Index down 0.11% [1] - Total market turnover was 1.93 trillion yuan, a decrease of 501 billion yuan compared to the previous trading day, with over 2700 stocks declining [1] Index Performance - Shanghai Composite Index: 3972.03, down 18.46 points (-0.46%) [2] - Shenzhen Component Index: 13202.00, down 14.03 points (-0.11%) [2] - ChiNext Index: 1526.46, down 12.26 points (+0.81%) [2] - Other indices such as the CSI 300 and CSI 500 also showed declines [2] Sector Performance - Lithium carbonate futures hit the daily limit, with lithium mining concepts continuing to surge, leading to stocks like Shengxin Lithium Energy and Yahua Group reaching the daily limit [3] - The military and shipbuilding sectors saw gains, with Jianglong Shipbuilding hitting a 20% limit up [3] - The AI application concept was active, with stocks like Xuanya International reaching the daily limit [3] - Conversely, the pharmaceutical sector experienced a broad decline, with stocks like Shuyou Pingmin dropping over 6% and Kexing Pharmaceutical nearly 8% [3] - Other sectors such as precious metals, cultivated diamonds, photovoltaic equipment, and medical devices also faced significant declines [3]

Market Overview - On November 17, major A-share indices collectively declined, with the Shanghai Composite Index falling by 0.46% to 3972 points, the Shenzhen Component Index down by 0.11%, and the ChiNext Index decreasing by 0.2% [1][2] - The trading volume in the Shanghai and Shenzhen markets was 1.91 trillion yuan, a decrease of 47.3 billion yuan compared to the previous trading day [1] Sector Performance - The military equipment and military information sectors saw significant gains, with Zhongfu Information hitting the daily limit up of 20% [4] - The Fujian and free trade zone sectors experienced a surge, with multiple stocks including Hongxiang Co., Zhongfutong, and Haixia Innovation also reaching the daily limit up of 20% [6] - The lithium carbonate futures contract hit the daily limit up, boosting the salt lake lithium extraction sector, with Shengxin Lithium Energy and Jinyuan Co. also reaching the daily limit up [8] - The aquaculture sector was active, with stocks like Zhongshui Fishery and Kaichuang International hitting the daily limit up [12] - AI application concepts were prominent, with stocks like BlueFocus and Jiechuang Intelligent seeing significant increases [10] Notable Stocks - Zhongfu Information rose by 20% to 17.82 yuan, while Beifang Changlong increased by 19.57% to 175.77 yuan [5] - Hongxiang Co. and Zhongfutong both saw a 20% increase, reaching 8.69 yuan and 22.54 yuan respectively [7] - Shengxin Lithium Energy increased by 10.01% to 35.93 yuan, while Jinyuan Co. rose by 9.98% to 6.28 yuan [9] Declining Sectors - The precious metals sector declined, with stocks like Zhaojin Gold and Hunan Silver dropping over 3% [14] - The pharmaceutical sector experienced a downturn, with stocks such as Kexing Pharmaceutical and Shutaishen falling over 7% [16] Market Sentiment - Recent geopolitical tensions, including remarks from Japanese Prime Minister Fumio Kishida and military exercises in the Yellow Sea, have heightened uncertainty in the market [4][12] - The U.S. government shutdown resolution has reduced the short-term appeal of gold as a safe-haven asset, contributing to the decline in precious metals [14]

Market Overview - The market experienced fluctuations with the three major indices narrowing their declines towards the end of the trading session [1][2] - The Shanghai Composite Index closed at 3972.03 points, down 0.46%; the Shenzhen Component Index closed at 13202.00 points, down 0.11%; and the ChiNext Index closed at 3105.20 points, down 0.20% [2] Sector Performance - The CPO concept stocks rebounded near the close, with Tengjing Technology hitting a 20% limit up, and Dekeli, Changxin Bochuang, Guangku Technology, and Zhongji Xuchuang also showing significant gains [1] - Huawei's computing power concept remained strong throughout the day, with Zhongfu Information and Borui Data both hitting a 20% limit up [1] - The AI application sector was active, with stocks like 360, Xuan Ya International, and Aerospace Development reaching their daily limit up [1] - Conversely, the precious metals sector faced adjustments, with Zhaojin Gold leading the declines [1] - The innovative drug sector saw widespread losses, with Kexing Pharmaceutical experiencing significant declines [1] Summary of Declines - Overall, there were more declining stocks than advancing ones, with over 2700 stocks falling [1]

Market Overview - Major A-share indices collectively declined today, with the Shanghai Composite Index falling by 0.46% to 3972 points, the Shenzhen Component down by 0.11%, and the ChiNext Index decreasing by 0.2% [1] - The total market turnover was 1.93 trillion yuan, a decrease of 501 billion yuan compared to the previous trading day, with over 2700 stocks declining [1] Sector Performance - Lithium carbonate futures hit the daily limit, with lithium mining concepts continuing to surge, leading to stocks like Shengxin Lithium Energy and Yahua Group reaching the daily limit [1] - The Fujian sector remained active, with Xiamen XGMA achieving five consecutive daily limits in ten days [1] - The military and shipbuilding sectors saw gains, with Jianglong Shipbuilding hitting the daily limit [1] - The aquaculture sector rose, with Kaichuang International also reaching the daily limit [1] - AI application concepts were active, with Sora and Zhipu AI leading the gains, and Xuanya International hitting the daily limit [1] - Other notable sectors with significant gains included Web 3.0, Kuaishou concepts, and Xinchuang [1] Declining Sectors - The pharmaceutical sector experienced a broad decline, with pharmaceutical commerce, recombinant proteins, weight-loss drugs, innovative drugs, and CROs leading the losses; Shuyuan Pingmin fell over 6%, and Kexing Pharmaceutical dropped nearly 8% [1] - The precious metals sector weakened, with Zhaojin Gold leading the decline [1] - Other sectors with notable declines included cultivated diamonds, photovoltaic equipment, medical devices, and insurance [1]

Core Viewpoint - The A-share market shows a mixed trend with the innovative drug sector experiencing a pullback, while the "20CM Innovative Drug New Species" ETF from Huatai-PineBridge (589120) has seen a net subscription of over 110 million yuan in the past 20 trading days despite a nearly 3% decline today [1][5]. Group 1: Market Performance - As of 14:02 on November 17, the innovative drug ETF has decreased by nearly 3%, continuing its pullback trend [1]. - The index components of the innovative drug ETF have all retreated, with notable declines including Elysium and Zai Lab dropping over 4%, and others like BeiGene and Eucure Biopharma falling over 3% [3][4]. Group 2: Company Announcements - On November 17, Sinovac Biotech announced a share transfer plan where shareholder Shenzhen Keyi Pharmaceutical Holdings intends to transfer 10.06 million shares, representing 5% of the total share capital, for operational needs [5]. - Eucure Biopharma reported that its Vice President and CFO has completed a share reduction plan, having originally held 571,400 shares (0.14% of total shares) and planned to reduce up to 128,900 shares [5]. Group 3: Sector Analysis - The innovative drug sector showed signs of recovery last week due to accelerated overseas clinical trials and positive earnings reports, with BeiGene reporting a strong Q3 2025 performance with revenue of $1.412 billion, a 41% year-on-year increase [6][7]. - Analysts suggest that the recent volatility in some stocks does not indicate the end of the market logic, and a new round of innovative drug market opportunities may emerge [6][7]. - The innovative drug sector is expected to enter a harvest period, supported by policy, innovation upgrades, and normalized overseas business development [7].